Synthekine has raised $289.5M across 2 funding rounds, plus 1 undated round.
Synthekine is backed by Deerfield Management and Janus Henderson Investors, part of the $313 million the clinical-stage biotech has raised from investors since its 2019 founding to fund its cytokine therapeutics pipeline.
2 funding rounds, the latest highlighted.
No date is disclosed for this round.
Other undisclosed investors. $82M raised, led by Canaan Partners, Samsara BioCapital, The Column Group.
No filing has been made.
2 dated rounds, newest first.
Canaan PartnersLEADSSamsara BioCapitalLEADRRA Capital ManagementBBain Capital Life SciencesSynthekine is a biotechnology company that applies protein engineering platforms to develop cytokine therapeutics for cancer and autoimmune disease, aiming to unlock the efficacy of cytokines while avoiding the toxicity that comes from their pleiotropic effects on the immune system.
Synthekine's total funding stands at $289.5M over 3 rounds.
Synthekine's most recent round was Series B, raising $107.5M in June 2021.
Synthekine's lead investors include Deerfield Management and Janus Henderson Investors.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
